Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans

por Yu, Tianzhou, Jin, Shihan, Li, Chang, Chambers, James D., Hlávka, Jakub P.
Publicado 2023

Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials

por Yu, Jeffrey C., Hlávka, Jakub P., Joe, Elizabeth, Richmond, Frances J., Lakdawalla, Darius N.
Publicado 2022

Macroeconomic consequences of the COVID-19 pandemic()

por Walmsley, Terrie, Rose, Adam, John, Richard, Wei, Dan, Hlávka, Jakub P., Machado, Juan, Byrd, Katie
Publicado 2023

Cost-effectiveness models for Alzheimer’s disease and related dementias: IPECAD modeling workshop cross-comparison challenge

por Handels, Ron L.H., Green, Colin, Gustavsson, Anders, Herring, William L., Winblad, Bengt, Wimo, Anders, Sköldunger, Anders, Karlsson, Andreas, Anderson, Robert, Belger, Mark, Brück, Chiara, Espinosa, Robert, Hlávka, Jakub P., Jutkowitz, Eric, Lin, Pei-Jung, Mendez, Mauricio Lopez, Mar, Javier, Shewmaker, Peter, Spackman, Eldon, Tafazzoli, Ali, Tysinger, Bryan, Jönsson, Linus
Publicado 2023